| Generic name | Cladribine |
| Pronunciation | KLAD-dri-been |
| Brand name(s), other common name(s) | Leustatin®, 2-CdA |
| Drug type | Antimetabolite |
| How the drug is given | Intravenously (IV) |
Indications and Usage
Cladribine is FDA approved to treat people who have active hairy cell leukemia. It is also used to treat some other types of leukemia and lymphoma.
Side effects needing medical attention
Black, tarry stools; blood in urine or stool; hoarseness; lower back or side pain; painful or difficult urination or unusual decrease in urination; pinhead-sized red spots on skin or rash; fever; chills; cough; shortness of breath; unusual bleeding or bruising; unusual tiredness or weakness; pain or redness at site of injection; stomach pain; swelling of feet or lower legs; unusually fast heartbeat; fatigue; nausea; decreased appetite; vomiting; diarrhea; constipation; headache; itching; muscle or joint pain; sweating; trouble sleeping; weakness.
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.